Gilead Sciences (NASDAQ:GILD) : Currently there are 14 street experts covering Gilead Sciences (NASDAQ:GILD) stock. The most bullish and bearish price target for the stock is $135 and $96 respectively for the short term. The average price target of all the analysts comes to $115.71. The estimated standard deviation from the target is $11.72.
Shares of Gilead Sciences Inc. appreciated by 0.06% during the last five trading days but lost 3.11% on a 4-week basis. Gilead Sciences Inc. has dropped 10.87% during the last 3-month period . Year-to-Date the stock performance stands at -16.7%. Also, Gabelli & Co initiates coverage on Gilead Sciences (NASDAQ:GILD). Gabelli & Co has a Buy rating on the shares. The rating by the firm was issued on June 1, 2016.
Gilead Sciences (NASDAQ:GILD) : 17 analysts are covering Gilead Sciences (NASDAQ:GILD) and their average rating on the stock is 1.94, which is read as a Buy. 8 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Gilead Sciences (NASDAQ:GILD) also receives 2 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 7 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Gilead Sciences (NASDAQ:GILD): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $82.27 and $81.53 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $83.42. The buying momentum continued till the end and the stock did not give up its gains. It closed at $83.42, notching a gain of 1.40% for the day. The total traded volume was 9,706,528 . The stock had closed at $82.27 on the previous day.
In an insider trading activity, The director officer (President and CEO), of Gilead Sciences Inc, Milligan John F had unloaded 112,000 shares at $86.92 per share in a transaction on June 6, 2016. The total value of transaction was $9,735,040. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.